

1 **Hypothalamic Gliosis is Associated With Multiple Cardiovascular Disease Risk Factors**

2 Authors: Justin Lo, MS ^a; Susan J Melhorn, PhD ^b; Sarah Kee ^b; Kelsey LW Olerich, MD, PhD ^c;
3 Alyssa Huang, MD ^d; Dabin Yeum, PhD ^b; Alexa Beiser, PhD ^e; Sudha Seshadri, MD ^f; Charles De
4 Carli, MD ^g; Ellen A Schur, MD, MS ^b

5
6 ^a School of Medicine, University of Washington, Seattle, WA

7 ^b Department of Medicine, University of Washington, Seattle, WA

8 ^c Department of Obstetrics & Gynecology, Division of Maternal-Fetal Medicine, University of
9 Washington, Seattle, WA

10 ^d Department of Pediatrics, University of Washington, Seattle, WA

11 ^e School of Public Health, Boston University, Boston, MA

12 ^f Department of Neurology, University of Texas Health Science Center at San Antonio, San
13 Antonio, TX

14 ^g Department of Neurology, University of California, Davis, Davis, CA

15

16 Short title: Hypothalamic Gliosis and Cardiometabolic Risk

17

18 Corresponding author: Ellen A Schur

19 ellschur@uw.edu

20 UW Medicine Diabetes Institute, 750 Republican Street, Box 358062, Seattle, WA 98109

21

22 Word count: 8392

23 Abstract

24

25 Background

26 Hypothalamic gliosis is mechanistically linked to obesity and insulin resistance in rodent models.
27 We tested cross-sectional associations between radiologic measures of hypothalamic gliosis in
28 humans and clinically relevant cardiovascular disease risk factors, as well as prevalent coronary
29 heart disease.

30

31 Methods

32 Using brain MRI images from Framingham Heart Study participants (N=867; mean age, 55
33 years; 55% females), T2 signal intensities were extracted bilaterally from the region of interest
34 in the mediobasal hypothalamus (MBH) and reference regions in the amygdala (AMY) and
35 putamen (PUT). T2 signal ratios were created in which greater relative T2 signal intensity
36 suggests gliosis. The primary measure compared MBH to AMY (MBH/AMY); a positive control
37 ratio (MBH/PUT) also assessed MBH whereas a negative control (PUT/AMY) did not. Outcomes
38 were BMI, HDL-C, LDL-C, fasting triglycerides, and the presence of hypertension (n=449),
39 diabetes mellitus (n=66), metabolic syndrome (n=254), or coronary heart disease (n=25).
40 Dietary risk factors for gliosis were assessed in a prospective analysis. Statistical testing was
41 performed using linear or logistic regression.

42

43 Results

44 Greater MBH/AMY T2 signal ratios were associated with higher BMI ($\beta = 21.5$ [95% CI, 15.4–
45 27.6]; $P < 0.001$), higher fasting triglycerides ($\beta = 1.1$ [95% CI, 0.6–1.7]; $P < 0.001$), lower HDL-C (β
46 $= -20.8$ [95% CI, -40.0 to -1.6]; $P = 0.034$), and presence of hypertension (odds ratio, 1.2 [95%
47 CI, 1.1–1.4]; $P = 0.0088$), and the latter two were independent of BMI. Findings for diabetes
48 mellitus were mixed and attenuated by adjusting for BMI. Metabolic syndrome was associated
49 with MBH/AMY T2 signal ratios (odds ratio, 1.3 [95% CI, 1.1–1.6]; $P < 0.001$). Model results were
50 almost uniformly confirmed by the positive control ratios, whereas negative control ratios that
51 did not test the MBH were unrelated to any outcomes (all $P \geq 0.05$). T2 signal ratios were not
52 associated with prevalent coronary heart disease (all $P > 0.05$), but confidence intervals were
53 wide. Self-reported percentages of macronutrient intake were not consistently related to future
54 T2 signal ratios.

55

56 Conclusions

57 Using a well-established study of cardiovascular disease development, we found evidence
58 linking hypothalamic gliosis to multiple cardiovascular disease risk factors, even independent of
59 adiposity. Our results highlight the need to consider neurologic mechanisms to understand and
60 improve cardiometabolic health.

61

62 Word count: 350

63 Non-standard Abbreviations and Acronyms

64

65	AgRP	agouti-related peptide
66	AMY	amygdala
67	BMI	body mass index
68	CHD	coronary heart disease
69	CNS	central nervous system
70	CVD	cardiovascular disease
71	DM	diabetes mellitus
72	FDR	false discovery rate
73	FFQ	food frequency questionnaire
74	FHS	Framingham Heart Study
75	HDL-C	high-density lipoprotein cholesterol
76	HTN	hypertension
77	LDL-C	low-density lipoprotein cholesterol
78	MBH	mediobasal hypothalamus
79	MetS	metabolic syndrome
80	MRI	magnetic resonance imaging
81	POMC	pro-opiomelanocortin
82	PUT	putamen
83	PVN	paraventricular nucleus
84	ROI	region of interest
85	SNA	sympathetic nerve activity
86	T1D	type 1 diabetes
87	T2D	type 2 diabetes

88 Introduction

89 Obesity, hypertension (HTN), metabolic syndrome (MetS), and type 2 diabetes (T2D) are well-
90 established risk factors for increased cardiovascular disease (CVD) morbidity and mortality.
91 However, central nervous system (CNS) involvement in the pathogenesis of CVD risk factors,
92 including obesity and T2D, is increasingly recognized.¹ A robust preclinical literature
93 demonstrates that diet-induced obesity in animal models is causally related to cellular
94 inflammatory responses in the hypothalamus.² Furthermore, T2D is linked to the remodeling of
95 extracellular matrix structures that scaffold neurons and their synaptic connections.³ In
96 humans, *ex vivo* histopathological and *in vivo* neuroimaging studies support that cellular and
97 tissue-level alterations consistent with hypothalamic gliosis are present in the human
98 hypothalamus in association with obesity and metabolic disease.¹ Prospective studies further
99 support a role in obesity and T2D pathogenesis by showing that the extent of gliosis, defined as
100 proliferation and inflammatory activation of glia, is associated with weight gain and progressive
101 insulin resistance in children and adults with overweight or obesity.^{4,5} Moreover, arcuate
102 nucleus inflammation may mediate the increased atherogenic risk associated with
103 hypogonadism in males.⁶ Further studies have linked hypothalamic inflammation to MetS, T2D,
104 and impaired glucose tolerance.^{5,7,8} Therefore, hypothalamic inflammation and gliosis could
105 indirectly increase the risk of CVD by promoting metabolic dysregulation, chronic systemic
106 inflammation, and/or atherogenic lipid profiles.

107 Alternatively, diet-induced hypothalamic inflammation in the MBH and its arcuate
108 nucleus could directly contribute to CVD development. The arcuate nucleus receives sensory
109 inputs and transmits intra- and extra-hypothalamic communications to govern homeostatic

110 regulation of key metabolic functions including energy balance, feeding behavior, and
111 maintenance of circulating glucose, but also sympathetic nerve activity (SNA).⁹ The latter
112 involves reciprocal inputs, primarily via the paraventricular nucleus, that can increase
113 sympathetic tone, peripheral vascular resistance, and, hence, blood pressure.¹⁰ Based on these
114 delineated neuronal pathways, inflammation and gliosis affecting the arcuate nucleus has the
115 potential to underlie obesity-associated increases in blood pressure and prevalence of HTN.
116 This has yet to be investigated and offers a route, separate from the above-noted metabolic
117 conditions, whereby CVD risk could be elevated via a CNS etiology. In summary, the
118 accumulated literature suggests hypothalamic inflammation and gliosis could influence CVD
119 development. We therefore investigated, in the Framingham Heart Study (FHS), the
120 associations of multiple cardiometabolic risk factors as well as prevalent coronary heart disease
121 (CHD) with radiologically assessed measures of hypothalamic gliosis. We also prospectively
122 examined dietary risk factors for hypothalamic gliosis based on self-reported dietary intake.

123

124 **Methods**

125 All data used in the analyses were shared through the FHS Repository and are available by
126 request for approved projects. JL had full access to the data and is responsible for the integrity
127 of the data analysis in the study.

128 **Study population**

129 In this cross-sectional study, 905 MRI images were provided from magnetic resonance imaging
130 (MRI) exams conducted on the FHS Offspring and Generation 3 cohorts (Figure S1). The FHS is a
131 longitudinal, multigenerational observational cohort study investigating cardiovascular risk

132 factors. FHS cohort recruitment and enrollment are described in detail elsewhere.^{11,12} Brain MRI
133 was added to the FHS to investigate brain aging.¹³ We evaluated 3T MRI images assessed
134 between 2012 and 2018 in relation to cardiovascular health indicators measured in the
135 Offspring (examination 9, 2011–2014, n=25) and Generation 3 (examination 2, 2009–2011,
136 n=14; examination 3, 2016–2019, n=828) cohorts. For the majority of the sample, brain MR
137 imaging was conducted in proximity to examination 3, on average, –0.3 years (range, –3.1 to
138 2.3 years) before examination 3 for Generation 3 cohort participants. For the remaining
139 participants, the MRI occurred an average of 5.6 years (range, 2.5–9.2 years) after examination
140 9 for Offspring Cohort participants and 6.4 years (range, 5.9–7.1 years) after examination 2 for
141 Generation 3 participants without examination 3 data. 35 MRI images were uninterpretable in
142 regions of interest (ROIs), while 3 MRI images were repeated scans from the same individual.
143 The total sample size included 867 individuals with unique MRI images and ratable T2-signal
144 intensities in ROIs. Those with missing data for certain covariates or outcomes were excluded
145 from relevant sub-analyses. For triglyceride analyses, we excluded individuals with fasting
146 triglyceride concentrations above 500 mg/dL (n=4).

147 [Outcomes of interest](#)

148 Outcomes of interest in this study were cardiovascular risk factors including body mass index
149 (BMI), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C),
150 fasting triglycerides, HTN, diabetes mellitus (DM), and MetS, as well as prevalent coronary heart
151 disease (CHD). BMI was calculated from height and weight measurements. HDL-C, LDL-C, and
152 fasting (at least 8 hours prior to blood sample collection) triglycerides were measured in
153 ethylenediaminetetraacetic acid serum tests. The presence of HTN was based on the American

154 Heart Association stage 1 and stage 2 HTN definitions as either systolic blood pressure greater
155 than or equal to 130 mmHg, diastolic blood pressure greater than or equal to 80 mmHg, and/or
156 receiving treatment for HTN.¹⁴ DM was defined as either fasting blood glucose greater than or
157 equal to 126 mg/dL, random blood glucose greater than or equal to 200 mg/dL, and/or
158 treatment for DM. Distinction between type 1 diabetes (T1D) and T2D was not ascertained but
159 most cases were assumed to be T2D, as discussed in previous literature.¹⁵ MetS was defined as
160 having 3 or more criteria of metabolic abnormalities according to the American Heart
161 Association and the National Heart, Lung, and Blood Institute definition¹⁶: 1) systolic blood
162 pressure greater than or equal to 130 mmHg, diastolic blood pressure greater than or equal to
163 85 mmHg, or receiving treatment for HTN; 2) fasting blood glucose greater than or equal to 100
164 mg/dL or receiving treatment for elevated blood glucose; 3) HDL-C less than 40 mg/dL in males
165 or 50 mg/dL in females or receiving treatment for low HDL-C; 4) triglycerides greater than or
166 equal to 150 mg/dL or receiving treatment for high triglycerides; 5) waist circumference greater
167 than or equal to 102 cm for males or 88 cm for females. Finally, CHD was defined as
168 manifestations of CHD before or during the FHS study period, including myocardial infarction,
169 coronary insufficiency, angina pectoris, sudden death from CHD, and non-sudden death from
170 CHD, and was adjudicated by FHS investigators.

171 Dietary Exposures

172 In a prospective cohort analysis, the relation of dietary exposures to subsequent MRI findings
173 was tested. Dietary exposures were collected from a Food Frequency Questionnaire (FFQ)
174 administered at the FHS exam prior to MRI acquisition (Offspring cohort, examination 8;
175 Generation 3 cohort, examination 2). Daily consumptions of the proportions of total fat, total

176 carbohydrates, total protein, total sugar, fructose, sucrose, and saturated fat of total energy
177 intake were calculated by dividing each dietary exposure intake (kilocalories consumed) by the
178 average daily caloric intake. 51 participants were missing FFQ data and 2 participants with
179 implausible values for the proportions of total fat and saturated fat were removed from all
180 dietary analyses, leaving a total sample of N=814. There was a greater percentage of females in
181 the group of participants with FFQ data compared to those without; otherwise, the two groups
182 did not differ in other relevant characteristics such as age, smoking status, and BMI (data not
183 shown).

184 [Covariates](#)

185 Age, sex, and smoking status were collected and reported in the FHS exam data. Information on
186 an individual's treatment status for HTN, DM, and lipid levels was determined from both self-
187 reported exam data and medication review. Physical activity was captured based on a physical
188 activity index derived from self-reported levels of activity during a typical 24-hour period.
189 Methods to construct the physical activity index are described in detail elsewhere.¹⁷

190 [MRI Acquisition and Analysis](#)

191 High-resolution T2-weighted axial brain images were analyzed in Horos Medical Image Software
192 by two independent raters (Figure 1). The image slice superior to the optic chiasm, with visible
193 optic tracts and mammillary bodies, was identified as the MBH slice of interest. The MBH ROI
194 was placed bilaterally in the anterior hypothalamic area adjacent to the 3rd ventricle to
195 encompass the region of the arcuate nucleus. Slices inferior and superior were selected based
196 on clear anatomical landmarks for the control ROIs (i.e., AMY and PUT). T2 signal intensities
197 were extracted bilaterally from the regions (i.e., MBH, AMY, and PUT). The signal intensities
198 were then used to create ratios for the left, right, and bilateral mean for our primary measure

199 (MBH/AMY) T2 signal ratio assessing hypothalamic gliosis, a positive control (MBH/PUT) T2
200 signal ratio, and a negative control (PUT/AMY) T2 signal ratio. T2 signal ratios were used to
201 capture MBH T2 signal relative to gray matter reference ROIs and to account for inter-subject
202 variability in signal intensity of the T2-weighted acquisitions. Calculated ratios from individual
203 raters were averaged and used in statistical analyses. The intraclass correlations between the
204 independent raters for the MBH/AMY, MBH/PUT, and PUT/AMY ratios were 0.71, 0.82, and
205 0.91, respectively.

206 [Statistical analysis](#)

207 Multiple linear regression was used to analyze continuous outcomes (i.e., BMI, LDL-C, HDL-C,
208 and triglycerides); multiple logistic regression was used to analyze binary outcomes (i.e., HTN,
209 DM, MetS, and CHD). Coefficients and confidence intervals are reported as the estimated
210 change in outcome per 1 unit difference in the predictor variable, while odds ratios and
211 confidence intervals are reported as the estimated change in odds per 1 SD difference in the
212 predictor variable. Fasting triglyceride levels were right-skewed and natural logarithm-
213 transformed for analysis. T2 signal ratios for the primary exposure, positive control, and
214 negative control predictors were natural logarithm transformed and used as predictors in the
215 models to satisfy conditions of normality. Age and sex were included as covariates in the base
216 model (Model 1). Current smoking status was added in subsequent models (Model 2), while risk
217 factor treatment status was further adjusted for outcomes except MetS (Model 3). BMI was
218 added in fully adjusted models when appropriate. Table S1 describes the full set of covariates
219 included in the models. We evaluated statistical significance using two-sided tests at the $P < 0.05$
220 level, uncorrected for multiple comparisons for our *a priori* outcomes, to test associations with

221 and without adjustment for confounders such as BMI. Statistics were computed in R version
222 4.2.3.

223 To test associations between dietary exposures and T2 signal ratios, both simple and
224 multiple linear regression models were conducted adjusting for age, sex, and time interval
225 between dietary exposure measurement and MRI measurement (years). A false discovery rate
226 (FDR) multiple comparison correction was applied to this set of analyses at $q < 0.05$. To explore if
227 the associations were modified by weight status, interaction terms between BMI categories
228 ($< 25 \text{ kg/m}^2$; $\geq 25 \text{ kg/m}^2$ & $< 30 \text{ kg/m}^2$; $\geq 30 \text{ kg/m}^2$) and each dietary exposure were added in
229 separate regression models. Diet analysis was conducted using R version 4.0.2.

230

231 Results

232 Participant characteristics

233 Characteristics from 867 individuals are presented in Table 1. The sample averaged 55 years of
234 age and was 55% female. The mean BMI was in the overweight range, whereas 34.6% of the
235 sample had a BMI in the obesity range. Current smoking (5.4%), diabetes treatment (5.4%), and
236 prevalent CHD (2.9%) were rare.

237 Body mass index (BMI)

238 MBH/AMY T2 signal ratios and BMI were positively associated (Figure 2A). The positive
239 association between MBH/AMY T2 signal ratios and BMI persisted after adjusting for age, sex,
240 smoking status, and diabetes treatment (Table 2). Coefficients estimate that a 0.1 unit increase
241 in the natural logarithm-transformed MBH/AMY T2 signal ratio would be associated with a 2.2
242 kg/m^2 (95% CI 1.5–2.8) higher BMI. The positive control (MBH/PUT) T2 signal ratio was also

243 positively associated with BMI in all models, whereas there were null associations for the
244 negative control (PUT/AMY) T2 signal ratio and BMI (Table 2).

245 HDL cholesterol (HDL-C)

246 There was a negative association between MBH/AMY T2 signal ratios and HDL-C (Figure 2B).

247 Negative associations were present at all levels of adjustment in models testing the primary

248 exposure (MBH/AMY T2 signal ratio) and the positive control (MBH/PUT) T2 signal ratio (Table

249 2), including after adjustment for BMI. PUT/AMY T2 signal ratios were not associated with HDL-

250 C concentrations (Table 2).

251 LDL cholesterol (LDL-C)

252 The primary exposure T2 signal ratios were not associated with LDL-C in model 1 (Figure 2C) nor

253 any further adjusted models (Table 2). The positive and negative control T2 signal ratios were

254 similarly not associated with LDL-C (Table 2).

255 Triglycerides

256 There were positive associations between the MBH/AMY T2 signal ratios and fasting

257 triglycerides in Model 1 (Figure 2D), as well as Models 2 and 3 (Table 2). However, the

258 magnitude of the association was reduced such that only a trend persisted after further

259 adjusting for BMI in the fully adjusted model (Table 2, $P=0.076$). In contrast, MBH/PUT T2 signal

260 ratios were uniformly positively associated with natural logarithm-transformed fasting

261 triglycerides, including after adjustment for BMI. PUT/AMY T2 signal ratios were not

262 significantly associated with fasting triglycerides (Table 2).

263 Hypertension

264 For all models, there were positive associations between MBH/AMY T2 signal ratios and the
265 presence of HTN (Figure 3). Model 1 estimates that a 1 SD difference in the natural-logarithm
266 transformed MBH/AMY T2 signal ratio is associated with a 1.4 (95% CI 1.2–1.6) times greater
267 odds of HTN diagnosis. Positive control T2 signal ratios were also positively associated with the
268 presence of HTN, except for in the fully adjusted model ($P=0.12$). No associations were found
269 with the negative control T2 signal ratio (Figure 3).

270 Diabetes mellitus (DM)

271 MBH/AMY T2 signal ratios were not associated with prevalent DM in any models (Figure 3).
272 MBH/PUT T2 signal ratios were associated with higher odds of prevalent DM (Figure 3), but not
273 in the fully adjusted model that included BMI ($P=0.21$). PUT/AMY T2 signal ratios were not
274 associated with DM (Figure 3).

275 Metabolic syndrome (MetS)

276 MBH/AMY T2 signal ratios were positively associated with prevalent MetS in all models (Figure
277 3), including after adjustment for age, sex, smoking status, and physical activity. The MBH/PUT
278 T2 signal ratios were also positively associated with prevalent MetS at all levels of adjustment,
279 whereas the PUT/AMY T2 signal ratios were not associated (Figure 3).

280 Coronary heart disease (CHD)

281 Among 25 individuals with prevalent CHD, 20 individuals were diagnosed with CHD prior to
282 their MRI exam. There were no associations between the MBH/AMY T2 signal ratios and
283 prevalent CHD (Figure 3), and all models returned coefficients with wide confidence intervals.

284 Neither positive nor negative control T2 signal ratios were associated with prevalent CHD
285 (Figure 3).

286 Sensitivity analyses

287 The timing of health information collection and MRI assessment across the sample varied by
288 individual and cohort. Results adjusted for time intervals between FHS health examination and
289 MRI examination are presented in Tables S3 and S4, and findings were unchanged from the
290 primary analysis.

291 Dietary exposures in relation to MBH gliosis

292 In analyses adjusting for age, sex, and time interval between dietary exposures and MRI, no
293 statistically significant prospective associations (Table S5) were found between self-reported
294 intake of total fat ($\beta=0.04$ [95% CI, -0.02 to 0.11]; $P=0.19$), total carbohydrates ($\beta=-0.04$ [95%
295 CI, -0.09 to 0.01]; $P=0.15$), total protein ($\beta = 0.09$ [95% CI, -0.04 to 0.22]; $P=0.19$), fructose ($\beta =$
296 -0.03 [95% CI, -0.22 to 0.17]; $P=0.78$), sucrose ($\beta = -0.08$ [95% CI, -0.20 to 0.04]; $P=0.19$), or
297 saturated fat ($\beta=0.12$ [95% CI, -0.04 to 0.29]; $P=0.14$) and the degree of MBH gliosis (natural
298 logarithm transformed MBH/AMY T2 signal ratio) assessed at MRI examinations conducted, on
299 average, 7 years after completion of FFQs. Negative associations were found between the
300 proportion of daily total carbohydrate intake ($\beta=-0.08$ [95% CI, -0.16 to 0.00]; $P=0.04$) and
301 sucrose intake ($\beta=-0.20$ [95% CI, -0.38 to -0.02]; $P=0.03$) and the positive control (MBH/PUT)
302 T2 signal ratio. These associations did not meet the FDR correction criteria at $q<0.05$. No
303 associations were found between dietary exposures and the negative control (PUT/AMY) T2
304 signal ratios (Table S5). Exploratory analyses demonstrated a significant interaction between
305 the BMI group and the proportion of daily saturated fat intake on the degree of MBH gliosis

306 (natural logarithm transformed MBH/AMY T2 signal ratio) after covariate adjustment (β -
307 $\text{int}=0.25$ [95% CI, 0.04–0.46]; $P\text{-int}=0.02$). As shown in Figure S2, stratified analyses revealed
308 opposing directions of slopes by BMI group (BMI<25 kg/m²: $\beta=-0.31$ [95% CI, –0.60 to –0.15];
309 $P=0.04$; 25 kg/m²≤BMI<30 kg/m²: $\beta=0.16$ [95% CI, –0.08 to 0.40]; $P=0.20$; BMI ≥30 kg/m²:
310 $\beta=0.22$ [95% CI, –0.08 to 0.53]; $P=0.14$).

311 Discussion

312 Using a well-established study of CVD development, we found evidence linking hypothalamic
313 gliosis to multiple CVD risk factors. Prior human studies indicate that obesity and metabolic
314 dysregulation, including glucose intolerance and T2D, are associated with histologic and
315 radiologic signs of MBH inflammation and gliosis.¹ In the largest sample studied to date, we
316 found strong positive associations of MBH gliosis with BMI and MetS, supporting previous
317 findings.^{7,18} Novel results linked MBH gliosis to low HDL-C and increased prevalence of HTN.
318 These associations persisted with adjustment for BMI, suggesting that it is not solely obesity-
319 related metabolic dysfunction driving the result, but that the function of central pathways
320 regulating circulating lipids and blood pressure could be directly impacted by glial cell
321 inflammatory responses in the MBH. Although we did not find associations between
322 hypothalamic gliosis and a clinical diagnosis of CHD, the sample size was small, and incident
323 disease was not assessed. In sum, these findings add to an expanding body of evidence
324 demonstrating the influence of CNS factors, namely hypothalamic inflammation and gliosis, on
325 the pathogenesis of cardiometabolic risk and, potentially, CVD itself.

326 Low levels of circulating HDL-C and high levels of LDL-C and triglycerides confer an
327 increased risk for CVD development and are strongly associated with obesity.^{19,20} However, few

328 studies have closely examined the relationship of dyslipidemia to diet-induced hypothalamic
329 inflammation. A study of 41 healthy adult males found that longer MBH T2 relaxation times
330 were associated with higher LDL-C levels but not associated with HDL-C or triglyceride levels.⁶ In
331 a cross-sectional study, Kreutzer et al. found no association between unilateral left-sided
332 MBH/AMY T2 signal ratios and triglyceride levels among 111 adults with and without obesity.²¹
333 Contrary to these smaller studies, we observed a strong negative association between MBH
334 gliosis and HDL-C. The negative association was present even after adjusting for BMI, a finding
335 that is consistent with the hypothesis that the severity of hypothalamic inflammation is directly
336 related to the worsening of obesity-associated metabolic dysregulation of both peripheral
337 glucose and blood lipids. Apolipoprotein A-I deficiency in mice produces a phenotype that
338 recapitulates many features of MetS including increased adiposity, visceral and hepatic fat
339 deposition, hypertriglyceridemia, glucose intolerance, and low HDL-C and is accompanied by
340 inflammation and reactive astrocytosis in the MBH.²² Intriguingly, administering reconstituted
341 human HDL-C normalized values of astrocyte inflammatory markers, indicating a potentially
342 protective role for HDL-C in reducing hypothalamic inflammation with concomitant
343 improvement in some features of MetS.²² On the contrary, randomized trials of
344 pharmacotherapies to increase HDL-C levels have not been shown to decrease CVD risk in
345 humans.^{23–25} Nonetheless, given the strong relationships between low HDL-C and altered
346 hypothalamic tissue structure in the current study, hypothalamic gliosis represents a novel,
347 largely unexplored mechanism to advance understanding of both the etiology of low HDL-C in
348 obesity and contradictory findings regarding the benefits of raising HDL-C for reducing CVD risk.
349 We also found evidence of a positive association between MBH/AMY T2 signal ratios and

350 fasting triglyceride concentrations. The association was attenuated when adjusting for BMI,
351 indicating that high levels of peripheral adiposity at least partially explain the relationship.
352 Lastly, we did not observe associations between T2 signal ratios and LDL-C. Nevertheless, the
353 MBH's role in energy homeostasis and the current findings should prompt further investigation
354 into dysregulation of circulating lipids by hypothalamic inflammation.

355 Preclinical evidence points to the role of the arcuate nucleus in altering blood pressure
356 through SNA.^{10,26} High-fat diets and obesity activate the arcuate nucleus, located within the
357 MBH, to alter SNA primarily through insulin and leptin signaling.^{10,26} Both hormones bind to
358 pro-opiomelanocortin (POMC) and agouti-related peptide (AgRP) neurons in the arcuate
359 nucleus, which in turn relay signals to other hypothalamic sites, such as the paraventricular
360 nucleus (PVN), an important regulator of SNA and blood pressure.^{27,28} Specifically, POMC
361 neurons release α -melanocyte-stimulating hormone that activates downstream melanocortin-4
362 receptors to increase SNA in the PVN, while AgRP neurons release neuropeptide Y (NPY) that
363 suppresses sympathoinhibitory effects in the PVN.²⁹⁻³³ Our results provide novel evidence that
364 MBH gliosis, a diet-induced phenomenon, is associated with HTN in humans. While the exact
365 mechanisms remain uncertain, hyperleptinemia, hyperinsulinemia, and/or local inflammation
366 itself may exacerbate arcuate nucleus-induced SNA, thereby raising blood pressure via the well-
367 defined neural circuitry outlined above. In the current study, associations were attenuated but
368 still present after adjusting for BMI, providing further rationale for investigating how
369 inflammation and gliosis in the arcuate nucleus region could evoke adiposity-independent
370 effects on neural circuits controlling blood pressure.

371 Hypothalamic gliosis has been linked to the development and progression of insulin
372 resistance. In a recent study in humans, Rosenbaum et al. showed the degree of MBH gliosis,
373 quantitatively assessed by MRI, was greater in individuals with obesity and impaired glucose
374 tolerance or T2D.⁵ This result was also observed in a separate study of women with obesity and
375 T2D.⁸ Following study subjects over time, Rosenbaum et al. found that MBH gliosis was related
376 to worsening insulin sensitivity over a 1-year follow-up period.⁵ Our current study did not
377 consistently detect an association between MBH T2 signal ratios and the presence of DM—
378 however, the point estimates trended in the positive direction but wide confidence intervals
379 made the association nonsignificant. The inability to distinguish between individuals with T1D
380 and T2D and the relatively low prevalence of DM in this FHS sample may have limited the ability
381 to detect a significant association. Studies assessing incident disease are needed to investigate
382 the role that MBH gliosis might play in T2D pathogenesis.

383 MetS was strongly associated with greater evidence of MBH gliosis. This is perhaps
384 unsurprising given that it is a composite clinical definition that includes CVD risk factors that
385 were individually associated with MBH gliosis. Kullman et al. previously demonstrated that
386 individuals with MetS had higher water content in regions of the brain including the
387 hypothalamus, thalamus, and fornix. Water content in these regions, as suggested by the
388 authors, may have resulted from an inflammatory response by glial cells increasing water
389 uptake, potentially damaging local microenvironments.⁷ Results from the present study are
390 consistent with Kullman et al. Such cross-sectional findings provide evidence that MetS and its
391 clinical components are related to hypothalamic inflammation, and potentially, structural
392 changes specific to the hypothalamus. Whether the severity of metabolic dysregulation (e.g.,

393 higher blood pressure, worse insulin resistance) or the presence of a greater number of CVD
394 risk factors is related to the degree of inflammation and structural damage presents a focus for
395 future investigations.

396 Hypothalamic gliosis is diet-induced in preclinical models.³⁴ We were unable to identify
397 consistent dietary predictors of MBH T2 signal ratios in humans in this prospective analysis.
398 However, the prospective association between lower daily proportion of total carbohydrate
399 consumption and greater evidence of gliosis, as assessed by the positive control T2 signal ratio,
400 suggests that the proportions of macronutrients in daily diet might be influential. Prior findings
401 in preclinical³⁵ and human²¹ studies highlight saturated fat consumption as a possible risk factor
402 for MBH gliosis in humans. Given the inverse relationship between carbohydrate and fat
403 consumption, the current findings of greater evidence of gliosis with lower carbohydrate intake
404 could be seen as supportive of the role of dietary fats in instigating hypothalamic inflammation.
405 Furthermore, the effect of saturated fat consumption on the degree of MBH gliosis was
406 modified by weight status. This result implies that those with overweight or obesity may have a
407 different susceptibility to gliosis related to saturated fat consumption than individuals
408 maintaining weight in the normal range. Further research capable of discerning risk and
409 protective factors for hypothalamic gliosis (e.g., genetics) in relation to precisely measured
410 dietary exposures is needed.

411 There are several strengths to this study. This is the largest study to date providing
412 evidence of associations between hypothalamic gliosis and multiple CVD risk factors, including
413 novel findings linking MBH gliosis with hypertension. Our outcomes of interest were high-
414 quality data measured and collected by FHS investigators. Limitations to this study include the

415 lack of statistical power to detect associations with CHD itself in a relatively young and healthy
416 study population with few CHD cases. Additionally, participants with longstanding CHD or DM
417 may have adapted lifestyle modification (e.g., diet changes or weight loss) with the potential to
418 affect hypothalamic gliosis. Furthermore, most subjects self-identified as White, limiting the
419 interpretation of our results to a select population, and we were not powered to determine
420 sex-specific associations. MRI images are an indirect measure of MBH gliosis; higher T2 signal
421 intensity can be due to local edema, tumors, or autoimmune inflammation, but in community-
422 based participants in an observational study, these pathologies are unlikely. Imaging variability
423 from factors such as B0 inhomogeneity may have limited our ability to detect smaller effect
424 sizes. Lastly, misclassification of dietary exposures could arise due to self-report methodology
425 and any changes in habitual intake that occurred during the several-year interim before MRI
426 images were captured.

427 In sum, the current study focuses attention on the CNS and on the evolving
428 understanding of how weight gain might relate to increased CVD risk.^{36,37} Weight gain and/or
429 dietary factors may promote hypothalamic inflammation which acts as a shared risk factor for
430 obesity and CVD that fails to fully resolve with lifestyle changes alone. While behavioral
431 interventions that improve metabolic status do not always reduce CVD risk,³⁸ GLP-1 agonists
432 that promote substantial weight loss as well as bariatric surgery do benefit cardiovascular
433 health.³⁹⁻⁴¹ Preclinical and human studies show improvement in hypothalamic inflammation
434 with liraglutide⁴² and bariatric surgery,^{8,43} respectively.

435 These robust cross-sectional findings support investigations to clarify the role of
436 hypothalamic gliosis in CVD pathogenesis. Future epidemiologic and clinical studies could

437 examine subclinical measures of disease, such as coronary artery calcium scores and carotid
438 intima-media thickness, to test whether hypothalamic gliosis is related to atherosclerosis prior
439 to the manifestation of clinical disease. Additional studies should determine whether evidence
440 of gliosis in the hypothalamus predicts incident CVD. More robust dietary assessments or
441 integration of objective biomarkers⁴⁴ could aid efforts to discover dietary stimulators of
442 hypothalamic inflammation in humans. Finally, preclinical studies in animal models of
443 atherosclerosis and HTN will be required to determine causal mechanisms whereby glial-cell
444 mediated hypothalamic inflammation and dysfunction might drive CVD risk.

445

446 [Acknowledgements](#)

447 From the Framingham Heart Study of the National Heart Lung and Blood Institute of the
448 National Institutes of Health and Boston University School of Medicine. This project has been
449 funded in whole or in part with Federal funds from the National Heart, Lung, and Blood
450 Institute, National Institutes of Health, Department of Health and Human Services, under
451 Contract No. 75N92019D00031. We would like to thank Yumei Feng Earley, Ph.D. for thoughtful
452 review of the manuscript and Nash Whitford for his assistance with exponential functions.

453

454 [Sources of Funding](#)

455 This work was supported by K24HL144917 (EAS), R01DK089036 (EAS), the University of
456 Washington Nutrition and Obesity Research Center (UW NORC) P30DK035816, AG054076,
457 P30AG066546, RF1AG059421 (SS), and P30AG072972 (CD). JL was supported by the University
458 of Washington Diabetes, Obesity and Metabolism Training Program (T32DK007247).

459

460 [Disclosures](#)

461 EAS has provided consultation to Amgen, Inc. The other authors report no conflicts.

462

463 [Supplemental Material](#)

464 Figure S1-S2

465 Table S1–S5

466 References

- 467 1. Sewaybricker LE, Huang A, Chandrasekaran S, Melhorn SJ, Schur EA. The Significance of
468 Hypothalamic Inflammation and Gliosis for the Pathogenesis of Obesity in Humans. *Endocr*
469 *Rev.* 2022;44:281–296.
- 470 2. García-Cáceres C, Balland E, Prevot V, Luquet S, Woods SC, Koch M, Horvath TL, Yi C-X,
471 Chowen JA, Verkhatsky A, et al. Role of astrocytes, microglia, and tanycytes in brain
472 control of systemic metabolism. *Nat Neurosci.* 2019;22:7–14.
- 473 3. Alonge KM, Mirzadeh Z, Scarlett JM, Logsdon AF, Brown JM, Cabrales E, Chan CK, Kaiyala
474 KJ, Bentsen MA, Banks WA, et al. Hypothalamic perineuronal net assembly is required for
475 sustained diabetes remission induced by fibroblast growth factor 1 in rats. *Nat Metab.*
476 2020;2:1025–1033.
- 477 4. Sewaybricker LE, Kee S, Melhorn SJ, Schur EA. Greater radiologic evidence of hypothalamic
478 gliosis predicts adiposity gain in children at risk for obesity. *Obesity (Silver Spring).*
479 2021;29:1770–1779.
- 480 5. Rosenbaum JL, Melhorn SJ, Schoen S, Webb MF, De Leon MRB, Humphreys M,
481 Utzschneider KM, Schur EA. Evidence That Hypothalamic Gliosis Is Related to Impaired
482 Glucose Homeostasis in Adults With Obesity. *Diabetes Care.* 2021;45:416–424.
- 483 6. Dorfman MD, Monfeuga T, Melhorn SJ, Kanter JE, Frey JM, Fasnacht RD, Chandran A, Lala
484 E, Velasco I, Rubinow KB, et al. Central androgen action reverses hypothalamic astrogliosis
485 and atherogenic risk factors induced by orchietomy and high-fat diet feeding in male
486 mice. *Am J Physiol Endocrinol Metab.* 2023;324:E461–E475.
- 487 7. Kullmann S, Abbas Z, Machann J, Shah NJ, Scheffler K, Birkenfeld AL, Häring H-U, Fritsche
488 A, Heni M, Preissl H. Investigating obesity-associated brain inflammation using
489 quantitative water content mapping. *Journal of Neuroendocrinology.* 2020;32:e12907.
- 490 8. van de Sande-Lee S, Melhorn SJ, Rachid B, Rodovalho S, De-Lima-Junior JC, Campos BM,
491 Pedro T, Beltramini GC, Chaim EA, Pareja JC, et al. Radiologic evidence that hypothalamic
492 gliosis is improved after bariatric surgery in obese women with type 2 diabetes. *Int J Obes*
493 *(Lond).* 2020;44:178–185.
- 494 9. Jais A, Brüning JC. Arcuate Nucleus-Dependent Regulation of Metabolism—Pathways to
495 Obesity and Diabetes Mellitus. *Endocr Rev.* 2021;43:314–328.
- 496 10. Guyenet PG, Stornetta RL, Souza GMP, Abbott SBG, Brooks VL. Neuronal Networks in
497 Hypertension: Recent Advances. *Hypertension.* 2020;76:300–311.

- 498 11. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of
499 coronary heart disease in families. The Framingham offspring study. *Am J Epidemiol.*
500 1979;110:281–290.
- 501 12. Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, D’Agostino RB, Fox CS,
502 Larson MG, Murabito JM, et al. The Third Generation Cohort of the National Heart, Lung,
503 and Blood Institute’s Framingham Heart Study: design, recruitment, and initial
504 examination. *Am J Epidemiol.* 2007;165:1328–1335.
- 505 13. Massaro JM, D’Agostino RB, Sullivan LM, Beiser A, DeCarli C, Au R, Elias MF, Wolf PA.
506 Managing and analysing data from a large-scale study on Framingham Offspring relating
507 brain structure to cognitive function. *Stat Med.* 2004;23:351–367.
- 508 14. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C,
509 DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017
510 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the
511 Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A
512 Report of the American College of Cardiology/American Heart Association Task Force on
513 Clinical Practice Guidelines. *Hypertension.* 2018;71:e13–e115.
- 514 15. Echouffo-Tcheugui JB, Niiranen TJ, McCabe EL, Henglin M, Jain M, Vasan RS, Larson MG,
515 Cheng S. An Early-Onset Subgroup of Type 2 Diabetes: A Multigenerational, Prospective
516 Analysis in the Framingham Heart Study. *Diabetes Care.* 2020;43:3086–3093.
- 517 16. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss
518 RM, Savage PJ, Smith SC, et al. Diagnosis and management of the metabolic syndrome: an
519 American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.
520 *Circulation.* 2005;112:2735–2752.
- 521 17. Shortreed SM, Peeters A, Forbes AB. Estimating the effect of long-term physical activity on
522 cardiovascular disease and mortality: evidence from the Framingham Heart Study. *Heart.*
523 2013;99:649–654.
- 524 18. Schur EA, Melhorn SJ, Oh S-K, Lacy JM, Berkseth KE, Guyenet SJ, Sonnen JA, Tyagi V,
525 Rosalynn M, De Leon B, et al. Radiologic evidence that hypothalamic gliosis is associated
526 with obesity and insulin resistance in humans. *Obesity (Silver Spring).* 2015;23:2142–2148.
- 527 19. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti
528 S, Faiella-Tommasino J, Forman DE, et al. 2018
529 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the
530 Management of Blood Cholesterol: A Report of the American College of
531 Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am
532 Coll Cardiol.* 2019;73:e285–e350.

- 533 20. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a
534 protective factor against coronary heart disease. The Framingham Study. *Am J Med.*
535 1977;62:707–714.
- 536 21. Kreutzer C, Peters S, Schulte DM, Fangmann D, Türk K, Wolff S, van Eimeren T, Ahrens M,
537 Beckmann J, Schafmayer C, et al. Hypothalamic Inflammation in Human Obesity Is
538 Mediated by Environmental and Genetic Factors. *Diabetes.* 2017;66:2407–2415.
- 539 22. Götz A, Lehti M, Donelan E, Striese C, Cucuruz S, Sachs S, Yi C-X, Woods SC, Wright SD,
540 Müller TD, et al. Circulating HDL levels control hypothalamic astrogliosis via apoA-I. *J Lipid*
541 *Res.* 2018;59:1649–1659.
- 542 23. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-
543 Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL
544 cholesterol levels receiving intensive statin therapy. *N Engl J Med.* 2011;365:2255–2267.
- 545 24. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T,
546 Tomson J, Wallendszus K, Craig M, Jiang L, et al. Effects of extended-release niacin with
547 laropiprant in high-risk patients. *N Engl J Med.* 2014;371:203–212.
- 548 25. Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger
549 C, Menon V, Montalescot G, et al. Evacetrapib and Cardiovascular Outcomes in High-Risk
550 Vascular Disease. *N Engl J Med.* 2017;376:1933–1942.
- 551 26. Stocker SD, Ferreira CB, Souza GM, Abbott SBG. Brain Pathways in Blood Pressure
552 Regulation. *Hypertension.* 2024;81:383–386.
- 553 27. Rahmouni K. Cardiovascular Regulation by the Arcuate Nucleus of the Hypothalamus.
554 *Hypertension.* 2016;67:1064–1071.
- 555 28. Dampney RA, Michelini LC, Li D-P, Pan H-L. Regulation of sympathetic vasomotor activity
556 by the hypothalamic paraventricular nucleus in normotensive and hypertensive states. *Am*
557 *J Physiol Heart Circ Physiol.* 2018;315:H1200–H1214.
- 558 29. Shi Z, Wong J, Brooks VL. Obesity: sex and sympathetics. *Biol Sex Differ.* 2020;11:10.
- 559 30. da Silva AA, Kuo JJ, Hall JE. Role of Hypothalamic Melanocortin 3/4-Receptors in Mediating
560 Chronic Cardiovascular, Renal, and Metabolic Actions of Leptin. *Hypertension.*
561 2004;43:1312–1317.
- 562 31. Shi Z, Li B, Brooks VL. Role of the Paraventricular Nucleus of the Hypothalamus in the
563 Sympathoexcitatory Effects of Leptin. *Hypertension.* 2015;66:1034–1041.
- 564 32. Cassaglia PA, Shi Z, Li B, Reis WL, Clute-Reinig NM, Stern JE, Brooks VL. Neuropeptide Y
565 acts in the paraventricular nucleus to suppress sympathetic nerve activity and its
566 baroreflex regulation. *J Physiol.* 2014;592:1655–1675.

- 567 33. Shi Z, Madden CJ, Brooks VL. Arcuate neuropeptide Y inhibits sympathetic nerve activity
568 via multiple neuropathways. *J Clin Invest*. 2017;127:2868–2880.
- 569 34. Douglass JD, Dorfman MD, Thaler JP. Glia: silent partners in energy homeostasis and
570 obesity pathogenesis. *Diabetologia*. 2017;60:226–236.
- 571 35. Valdearcos M, Robblee MM, Benjamin DI, Nomura DK, Xu AW, Koliwad SK. Microglia
572 dictate the impact of saturated fat consumption on hypothalamic inflammation and
573 neuronal function. *Cell Rep*. 2014;9:2124–2138.
- 574 36. Purnell JQ, Braffett BH, Zinman B, Gubitosi-Klug RA, Sivitz W, Bantle JP, Ziegler G, Cleary
575 PA, Brunzell JD. Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1
576 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of
577 Diabetes Interventions and Complications (DCCT/EDIC) Study. *Diabetes Care*.
578 2017;40:1756–1762.
- 579 37. Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-Weight
580 Fluctuations and Outcomes in Coronary Disease. *N Engl J Med*. 2017;376:1332–1340.
- 581 38. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M,
582 Crow RS, Curtis JM, Egan CM, et al. Cardiovascular effects of intensive lifestyle
583 intervention in type 2 diabetes. *N Engl J Med*. 2013;369:145–154.
- 584 39. Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 Receptor Agonists for the
585 Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.
586 *Circulation*. 2022;146:1882–1894.
- 587 40. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-
588 Lindberg S, Hovingh GK, Kahn SE, Kushner RF, et al. Semaglutide and Cardiovascular
589 Outcomes in Obesity without Diabetes. *N Engl J Med*. 2023;389:2221–2232.
- 590 41. van Veldhuisen SL, Gorter TM, van Woerden G, de Boer RA, Rienstra M, Hazebroek EJ, van
591 Veldhuisen DJ. Bariatric surgery and cardiovascular disease: a systematic review and meta-
592 analysis. *Eur Heart J*. 2022;43:1955–1969.
- 593 42. Liao T, Zhang S-L, Yuan X, Mo W-Q, Wei F, Zhao S-N, Yang W, Liu H, Rong X. Liraglutide
594 Lowers Body Weight Set Point in DIO Rats and its Relationship with Hypothalamic
595 Microglia Activation. *Obesity (Silver Spring)*. 2020;28:122–131.
- 596 43. Pané A, Videla L, Calvet À, Viaplana J, Vaqué-Alcázar L, Ibarzabal A, Rozalem-Aranha M,
597 Pegueroles J, Moize V, Vidal J, et al. Hypothalamic Inflammation Improves Through
598 Bariatric Surgery, and Hypothalamic Volume Predicts Short-Term Weight Loss Response in
599 Adults With or Without Type 2 Diabetes. *Diabetes Care*. 2024;dc232213.
- 600 44. Prentice RL, Vasan S, Tinker LF, Neuhouser ML, Navarro SL, Raftery D, Gowda GN,
601 Pettinger M, Aragaki AK, Lampe JW, et al. Metabolomics Biomarkers for Fatty Acid Intake

602 and Biomarker-Calibrated Fatty Acid Associations with Chronic Disease Risk in
603 Postmenopausal Women. *J Nutr.* 2023;153:2663–2677.

604

605 Figure Legends

606 Figure 1. Axial brain T2-weighted image with anatomic locations of MBH and reference regions
607 of interest. Representative MRI images and regions of interest (ROIs). **A)** The amygdala was
608 identified at the level of the optic chiasm (oc) which was, on average, one slice inferior to the
609 hypothalamus. **B)** Inset identified in A with representative bilateral placement of ROIs in the
610 amygdala. **C)** The mediobasal hypothalamus (MBH) was identified on the slice with distinct
611 optic tracts (ot) and visible mammillary bodies (mb) and is at the level of the superior colliculus
612 of the midbrain (superior to A). **D)** Inset identified in C with representative placement of
613 bilateral ROIs in the anterior hypothalamus, encompassing the location of the arcuate nucleus,
614 adjacent to the 3rd ventricle. **E)** The putamen was identified at a level of the frontal horn of the
615 lateral ventricles (with visible caudate head, internal capsule and globus pallidus). **F)** Inset
616 identified in E with representative placement of bilateral ROIs in the putamen. oc, optic chiasm;
617 MBH, mediobasal hypothalamus; ot, optic tract; 3V, 3rd ventricle; mb, mammillary body; fhLV,
618 frontal horn of the lateral ventricle; ca, caudate; it, internal capsule; gp, globus pallidus.

619

620 Figure 2. Sex- and age-adjusted associations of CVD risk factors with radiologic evidence of
621 hypothalamic gliosis by MBH/AMY T2 signal ratios. Scatterplots with linear fit lines of adjusted
622 associations between MBH/AMY T2 signal ratio and body mass index (BMI, A), HDL cholesterol
623 (HDL-C, B), LDL cholesterol (LDL-C, C), and natural logarithm transformed fasting triglycerides
624 (D). X-axis values represent MBH/AMY T2 signal ratios back-transformed from their natural
625 logarithm value in the distribution derived from the linear fit performed on the natural
626 logarithm transformed predictor variable. P-values correspond to the two-sided probability of
627 the estimated t-statistic for the coefficient of the predictor in Model 1. MBH, mediobasal
628 hypothalamus; AMY, amygdala.

629

630 Figure 3. Forest plot of odds ratios & 95% confidence intervals for T2 signal ratios and binary
631 outcomes related to cardiovascular risk and coronary heart disease. Results are from multiple
632 logistic regression models. MRI-assessed T2 signal ratios were natural logarithm transformed
633 and used as model predictors: MBH/AMY (primary), MBH/PUT (positive control), and PUT/AMY
634 (negative control). Black squares represent the point estimates of the ORs for each model's
635 predictor, and solid lines represent 95% CIs for the ORs. ORs and 95% CIs are presented as the
636 change in odds for the outcome per a 1 SD difference in natural logarithm-transformed T2
637 signal ratio. Arrows indicate that the width of the 95% CI lies outside of the figure axis. The
638 dashed vertical line signifies the null OR of 1. BMI, body mass index; HDL-C, high-density
639 lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ln(Triglycerides), natural
640 logarithm transformed fasting triglycerides; MBH, mediobasal hypothalamus; AMY, amygdala;
641 PUT, putamen. * Model 1 adjusted for age and sex. † Model 2 adjusted for model 1 covariates
642 plus smoking. ‡ Model 3 adjusted for model 2 covariates plus diabetes treatment for BMI
643 model or lipid treatment for HDL-C, LDL-C, and natural log-transformed triglycerides models. §
644 Fully adjusted model includes model 3 covariates plus BMI, when appropriate.

645 Table 1. Study population characteristics.

	Summary (N=867)
Age, years, mean (SD)	54.9 (8.8)
Sex	
Female, n (%)	476 (54.9)
Male, n (%)	391 (45.1)
Self-reported race	
White, n (%)	856 (98.7)
Black, n (%)	1 (0.1)
Other, n (%)	10 (1.2)
Smoking status*	
Does not smoke, n (%)	819 (94.6)
Currently smokes, n (%)	47 (5.4)
FHS physical activity index, mean (SD) [†]	36.0 (6.2)
Body mass index, kg/m ² , mean (SD)	28.6 (5.5)
BMI<25 kg/m ² , n (%)	240 (27.7)
25≤BMI<30 kg/m ² , n (%)	327 (37.7)
BMI≥30 kg/m ² , n (%)	300 (34.6)
Waist circumference, cm, mean (SD)	99.7 (14.4)
HDL cholesterol, mg/dL, mean (SD) [‡]	60.2 (20.0)
LDL cholesterol, mg/dL, mean (SD) [§]	106.3 (29.4)
Fasting triglycerides, mg/dL, mean (SD) ^{‡, , #}	111.8 (72.0)
Lipid treatment	
Not treated for lipids, n (%)	638 (73.6)
Treated for lipids, n (%)	229 (26.4)
Systolic blood pressure, mm Hg, mean (SD)	119.6 (14.0)
Diastolic blood pressure, mm Hg, mean (SD)**	76.0 (8.8)
Hypertension treatment***	
Not treated for hypertension, n (%)	641 (74.0)
Treated for hypertension, n (%)	225 (26.0)
Hypertension (HTN)	
Absence of HTN, n (%)	417 (48.2)
Prevalent HTN, n (%)	449 (51.8)
Blood glucose, mg/dL, mean (SD) [‡]	99.6 (20.0)
Diabetes mellitus treatment	
Not treated for diabetes, n (%)	820 (94.6)
Treated for diabetes, n (%)	47 (5.4)
Diabetes mellitus (DM) [‡]	
Absence of DM, n (%)	798 (92.4)
Prevalent DM, n (%)	66 (7.6)
Metabolic syndrome (MetS)	

Absence of MetS, n (%)	613 (70.7)
Prevalent MetS, n (%)	254 (29.3)
Coronary heart disease (CHD)	
Absence of CHD, n (%)	842 (97.1)
Prevalent CHD, n (%)	25 (2.9)
MBH/AMY T2 signal ratio, mean (SD)	1.27 (0.07)
MBH/PUT T2 signal ratio, mean (SD)****	1.72 (0.14)
PUT/AMY T2 signal ratio, mean (SD)****	0.74 (0.06)

646
647 *n=1 individual missing information about smoking status; †n=3 individuals missing information
648 about physical activity; ‡ n=2 individuals missing information on triglycerides, HDL cholesterol,
649 blood glucose levels, and diabetes mellitus status; § n=12 individuals missing information on
650 LDL cholesterol; || n=3 individuals excluded with fasting triglyceride concentrations greater
651 than 500 mg/dL; # n=20 individuals missing fasting triglyceride concentrations; **n=1 individual
652 missing information on DBP; *** n=1 individual missing information on hypertension
653 treatment; **** n=14 individuals missing MBH/PUT & PUT/AMY T2 signal ratios.

654 Table 2. Associations of quantitative MRI measures and continuous outcomes related to cardiovascular risk.

T2 signal ratio predictor and model		BMI		HDL-C		LDL-C		ln(Triglycerides)	
		Coefficient [95% CI]	P value	Coefficient [95%CI]	P value	Coefficient [95%CI]	P value	Coefficient [95%CI]	P value
MBH/AMY	Model 1*	22.2 [16.0, 28.3]	<0.001	-47.3 [-67.5, -27.1]	<0.001	18.2 [-16.5, 52.8]	0.30	1.2 [0.6, 1.7]	<0.001
	Model 2†	22.2 [16.0, 28.4]	<0.001	-47.3 [-67.4, -27.1]	<0.001	17.7 [-16.9, 52.4]	0.32	1.2 [0.6, 1.7]	<0.001
	Model 3‡	21.5 [15.4, 27.6]	<0.001	-46.3 [-66.2, -26.3]	<0.001	21.5 [-11.3, 54.4]	0.20	1.1 [0.6, 1.7]	<0.001
	Fully adjusted§	-20.8 [-40.0, -1.6]	0.034	12.5 [-21.2, 46.3]	0.47	0.5 [-0.0, 1.0]	0.076
MBH/PUT	Model 1*	12.7 [8.3, 17.0]	<0.001	-34.2 [-48.3, -20.2]	<0.001	-2.0 [-26.0, 22.1]	0.87	0.9 [0.5, 1.3]	<0.001
	Model 2†	12.9 [8.5, 17.2]	<0.001	-33.6 [-47.7, -19.5]	<0.001	-1.1 [-25.2, 23.0]	0.93	0.9 [0.5, 1.2]	<0.001
	Model 3‡	12.2 [7.9, 16.5]	<0.001	-32.3 [-46.3, -18.4]	<0.001	3.0 [-19.9, 25.9]	0.80	0.8 [0.4, 1.2]	<0.001
	Fully adjusted§	-17.9 [-31.2, -4.6]	0.0083	-3.0 [-26.3, 20.2]	0.80	0.5 [0.1, 0.8]	0.011
PUT/AMY	Model 1*	-2.5 [-7.4, 2.4]	0.32	14.5 [-1.3, 30.3]	0.072	17.4 [-9.2, 44.0]	0.20	-0.4 [-0.8, 0.1]	0.081
	Model 2†	-2.7 [-7.7, 2.2]	0.28	13.6 [-2.2, 29.5]	0.092	16.2 [-10.5, 42.9]	0.24	-0.3 [-0.8, 0.1]	0.11
	Model 3‡	-2.2 [-7.1, 2.6]	0.37	12.4 [-3.3, 28.1]	0.12	12.7 [-12.7, 38.2]	0.33	-0.3 [-0.8, 0.1]	0.11
	Fully adjusted§	9.7 [-4.8, 24.3]	0.19	13.7 [-11.7, 39.0]	0.29	-0.3 [-0.7, 0.1]	0.20

655

656 Results are from multiple linear regression models. MRI-assessed T2 signal ratios were natural logarithm transformed and used as
 657 model predictors: MBH/AMY (primary), MBH/PUT (positive control), and PUT/AMY (negative control). Coefficient and confidence
 658 intervals represent the estimated change in outcome per 1 unit difference in the log-transformed T2 signal ratio.

659

660 BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ln(Triglycerides),
 661 natural logarithm transformed fasting triglycerides; MBH, mediobasal hypothalamus; AMY, amygdala; PUT, putamen.

662


663 * Model 1 adjusted for age and sex.

664 † Model 2 adjusted for model 1 covariates plus smoking.

665 ‡ Model 3 adjusted for model 2 covariates plus diabetes treatment for BMI model or lipid treatment for HDL-C, LDL-C, and natural
 666 log-transformed triglycerides models.

667 § Fully adjusted model includes model 3 covariates plus BMI, when appropriate.

668 Figure 1. Axial brain T2-weighted image with anatomic locations of MBH and
669 reference regions of interest.




670

671 Representative MRI images and regions of interest (ROIs). **A)** The amygdala was identified at
672 the level of the optic chiasm (oc) which was, on average, one slice inferior to the hypothalamus.
673 **B)** Inset identified in A with representative bilateral placement of ROIs in the amygdala. **C)** The
674 mediobasal hypothalamus (MBH) was identified on the slice with distinct optic tracts (ot) and
675 visible mammillary bodies (mb) and is at the level of the superior colliculus of the midbrain
676 (superior to A). **D)** Inset identified in C with representative placement of bilateral ROIs in the
677 anterior hypothalamus, encompassing the location of the arcuate nucleus, adjacent to the 3rd
678 ventricle. **E)** The putamen was identified at a level of the frontal horn of the lateral ventricles
679 (with visible caudate head, internal capsule and globus pallidus). **F)** Inset identified in E with
680 representative placement of bilateral ROIs in the putamen.

681

682 oc, optic chiasm; MBH, mediobasal hypothalamus; ot, optic tract; 3V, 3rd ventricle; mb,
683 mammillary body; fhLV, frontal horn of the lateral ventricle; ca, caudate; it, internal capsule; gp,
684 globus pallidus.

685 Figure 2. Sex- and age-adjusted associations of CVD risk factors with radiologic
686 evidence of hypothalamic gliosis by MBH/AMY T2 signal ratios.




687

688 Scatterplots with linear fit lines of adjusted associations between MBH/AMY T2 signal ratio and
689 body mass index (BMI, A), HDL cholesterol (HDL-C, B), LDL cholesterol (LDL-C, C), and natural
690 logarithm transformed fasting triglycerides (D). X-axis values represent MBH/AMY T2 signal
691 ratios back-transformed from their natural logarithm value in the distribution derived from the
692 linear fit performed on the natural logarithm transformed predictor variable. P-values
693 correspond to the two-sided probability of the estimated t-statistic for the coefficient of the
694 predictor in Model 1.

695

696 MBH, mediobasal hypothalamus; AMY, amygdala

Figure 3. Forest plot of odds ratios & 95% confidence intervals for T2 signal ratios and binary outcomes related to cardiovascular risk and coronary heart disease.



Results are from multiple logistic regression models. MRI-assessed T2 signal ratios were natural logarithm transformed and used as model predictors: MBH/AMY (primary), MBH/PUT (positive control), and PUT/AMY (negative control). Black squares represent the point estimates of the ORs for each model's predictor, and solid lines represent 95% CIs for the ORs. ORs and 95% CIs are presented as the change in odds for the outcome per a 1 SD difference in natural logarithm-transformed T2 signal ratio. Arrows indicate that the width of the 95% CI lies outside of the figure axis. The dashed vertical line signifies the null OR of 1.

MBH, mediobasal hypothalamus; AMY, amygdala; PUT, putamen; OR, odds ratio, CI, confidence interval.

* Model 1 adjusted for age and sex.

† Model 2 adjusted for model 1 covariates plus smoking.

‡ Model 3 adjusted for model 2 covariates plus lipid treatment for hypertension and coronary heart disease models, presence of hypertension for diabetes mellitus models, or physical activity for metabolic syndrome models.

§ Fully adjusted model includes model 3 covariates plus BMI, when appropriate.